Education
About Us
Working with TipRanks
Follow Us
Definium Therapeutics (DFTX)
NASDAQ:DFTX
DFTX Stock Chart & Stats
$17.35
-$0.97(-11.96%)
At close: 4:00 PM EST
$17.35
-$0.97(-11.96%)
Day’s Range― - ―
52-Week Range$4.70 - $18.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.93M
Market Cap
$1.66B
Enterprise Value$1.67B
Total Cash (Recent Filing)$209.07M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Mar 05, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding98,509,280
10 Day Avg. Volume1,741,529
30 Day Avg. Volume1,933,720
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.03
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.21
Forecast
1Y Price Target
$35.89Price Target Upside106.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial CatalystsMultiple ongoing Phase 3 trials for the lead asset create several opportunities for positive top-line readouts in 2026 that could validate efficacy and materially increase valuation.
Financing And Cash RunwayA recent large equity financing extended cash runway into 2028, supporting advancement of pivotal programs and preparatory commercial activities without immediate funding pressure.
Regulatory DesignationFDA breakthrough designation for DT120 after a Phase IIb remission signal suggests an expedited regulatory pathway and raises the probability of earlier approval.
Bears Say
Cash Burn And Financing RiskHigh annual cash burn relative to resources could necessitate additional financing, raising dilution risk and creating execution uncertainty if market conditions tighten.
Controlled Substance Regulatory RiskAssociation with LSD and its Schedule I status introduces unique regulatory and legal hurdles that could delay approval or limit commercial pathways.
Treatment LogisticsTherapy requires an eight-hour inpatient visit, which could hinder patient adoption and complicate integration into routine clinical practice.
Definium Therapeutics News
DFTX FAQ
What was Definium Therapeutics’s price range in the past 12 months?
Definium Therapeutics lowest stock price was $4.70 and its highest was $18.70 in the past 12 months.
What is Definium Therapeutics’s market cap?
Definium Therapeutics’s market cap is $1.66B.
When is Definium Therapeutics’s upcoming earnings report date?
Definium Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 22 days.
How were Definium Therapeutics’s earnings last quarter?
Definium Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.501 by -$0.279.
Is Definium Therapeutics overvalued?
According to Wall Street analysts Definium Therapeutics’s price is currently Undervalued.
Does Definium Therapeutics pay dividends?
Definium Therapeutics does not currently pay dividends.
What is Definium Therapeutics’s EPS estimate?
Definium Therapeutics’s EPS estimate is -0.5.
How many shares outstanding does Definium Therapeutics have?
Definium Therapeutics has 98,509,280 shares outstanding.
What happened to Definium Therapeutics’s price movement after its last earnings report?
Definium Therapeutics reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.501. Following the earnings report the stock price went up 3.175%.
Which hedge fund is a major shareholder of Definium Therapeutics?
Currently, no hedge funds are holding shares in DFTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Definium Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.89 (106.86% Upside)
$35.89 (106.86% Upside)
Blogger Sentiment
Bullish
DFTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.40%
12-Months-Change
Fundamentals
Return on Equity
-85.59%
Trailing 12-Months
Asset Growth
-25.91%
Trailing 12-Months
Company Description
Definium Therapeutics
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
DFTX Earnings Call
Q3 2025
0:00 / 0:00
DFTX Stock 12 Month Forecast
Average Price Target
$35.89
▲(106.86% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.68% Insiders
5.46% Mutual Funds
0.04% Other Institutional Investors
83.54% Public Companies and Individual Investors